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Abstract
Connectivity mapping is a recently developed technique for discovering the underlying connections between different
biological states based on gene-expression similarities. The sscMap method has been shown to provide enhanced
sensitivity in mapping meaningful connections leading to testable biological hypotheses and in identifying drug candidates
with particular pharmacological and/or toxicological properties. Challenges remain, however, as to how to prioritise the
large number of discovered connections in an unbiased manner such that the success rate of any following-up investigation
can be maximised. We introduce a new concept, gene-signature perturbation, which aims to test whether an identified
connection is stable enough against systematic minor changes (perturbation) to the gene-signature. We applied the
perturbation method to three independent datasets obtained from the GEO database: acute myeloid leukemia (AML),
cervical cancer, and breast cancer treated with letrozole. We demonstrate that the perturbation approach helps to identify
meaningful biological connections which suggest the most relevant candidate drugs. In the case of AML, we found that the
prevalent compounds were retinoic acids and PPARc activators. For cervical cancer, our results suggested that potential
drugs are likely to involve the EGFR pathway; and with the breast cancer dataset, we identified candidates that are involved
in prostaglandin inhibition. Thus the gene-signature perturbation approach added real values to the whole connectivity
mapping process, allowing for increased specificity in the identification of possible therapeutic candidates.
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Introduction
Different biological states have their own characteristic gene-
expression profiles, and these profiles reflect the state of the cell
and offer an insight into possible effectors to influence the
phenotype. A feature of microarray gene expression profiles is the
ability to distinguish between disease states and that of normal
states [1–3]. The difference in gene expression can be used to
formulate a query gene signature based on pertinent genes
retrieved by statistical differentiation. This can form the basis of a
disease-gene-drug connection, with the discovery of potential
candidate therapeutics. Such a connection between divergent
fields has the ability to propose alternative treatments for diseases
that are often painstakingly acquired over extended periods of time
on a particular known effector/inhibitor [4].
The Connectivity Map concept was first introduced by Lamb
et al. (2006) as an endeavor to tackle one of the fundamental
challenges in biomedicine, to establish the connections between
genes, drugs, and diseases [3]. The underlying principle is that
gene expression differentiation can adequately characterise a
biological state, with which the formulation of a connection
between two states can be made by comparing their genomic
signatures. The key components of formulating such a connection
are 1) a core database of gene expression profiles, 2) a query gene
signature, and 3) an algorithm that utilises pattern matching to
establish connections [1]. As a further development upon the
initial Connectivity Map concept, Zhang and Gant (2008)
developed a simpler and unified framework for carrying out the
connectivity mapping exercise [5], which was implemented in
sscMap (statistically significant connections’ map) that offers
researchers the ability to make statistically significant connections
between query gene signatures (the gene lists to be analysed) and
reference profiles (the gene lists used as the reference in the
connectivity mapping process) [6].
Connectivity mapping methods, sscMap in particular, allow the
possibility of the use of alternative therapeutics and novel
applications of existing drugs [3,5,7]. The connectivity mapping
approach has been applied to studies to discover candidate
therapeutics to neuroblastoma and hepatocellular carcinoma
[8,9]. It was a useful resource in these instances as prognosis for
these types of cancers are particularly poor. This is an important
factor that enhances the potential opportunity offered by these
techniques. Other interesting techniques that have developed from
the original Connectivity Map concept have looked at addressing
the mode of action and molecular effects by way of a ‘‘drug
network (DN)’’ [10]. Iorio et al. developed a tool to explore the DN
and query it with undescribed compounds for classification.
Another area looked at by Iskar et al. was that of utilising filtering
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elucidate drug-induced feedback mechanisms using the Connec-
tivity Map [11]. sscMap differs from these approaches by
exploring the avenue of selecting robust candidates for the
potential to alter the phenotype of disease using a modified
framework of the original Connectivity Map. Through introducing
a new ranking and scoring scheme it provides safeguards and
protects against false positives. [5].
The application of a methodology that would allow enhanced
sensitivity in therapeutic candidate selection would offer an
attractive synergy with the sscMap concept. Through a method
of increasing the confidence in therapeutic potential it would
shorten the list of retrieved candidates and heighten the chance for
successful application. In order to make the best possible
connections between these states it is important that the selection
process is capable of predicting candidates accurately. The
sensitivity and specificity of sscMap ensure the return of
statistically significant connections and the accumulation of
therapeutic candidates, but it is how these are ranked to maximise
their effectiveness is of importance. To achieve this we introduced
a new concept, gene-signature perturbation, which helps to
discover meaningful biological connections that are robust and
stable against systematic small changes (perturbation). Briefly, this
test of robustness with connections between gene signatures and
reference profiles is obtained by omitting each gene (probeset)
once, with replacement, and witnessing its effect on the concurrent
listing of hypothesised therapeutic candidates. A perturbation
stability score (see the Methods section for detailed definition and
procedure) is calculated for each candidate, with a maximum score
of 1 indicating that the candidate therapeutic in question was
stable and robust against perturbation in the analysis. A decreasing
score would indicate that the candidates were not of sufficient
caliber to require immediate attention. The foundation of this
approach allows the user to have a list of potential candidate
compounds that have performed strongly amongst the built-in
core database of reference profiles. Extending this approach to
understand the therapeutic ‘strength’ in an unbiased way would
enhance the utility of sscMap. To assess this we have implemented
a method of this perturbation testing in order to rank candidate
compounds by their ability to withstand these slight changes to the
signature gene list.
We examined this approach on three publicly available datasets
from the GEO database [12]. We attained curated microarray
datasets for cervical cancer, acute myeloid leukemia and breast
cancer (letrozole treated) [13–15]. For each case study the raw data
were downloaded in Affymetrix CEL format and the relevant
information garnered from packages in the Bioconductor suite [16].
Acute myeloid leukemia (AML) is a disease with a particularly
poor prognosis. It is a disease where abnormal myeloid blood cells
are produced and accumulate in the peripheral blood and bone
marrow [17]. AML has high levels of genetic heterogeneity and
this makes targeted therapies challenging [18]. The GEO curated
dataset (GSE9476, of type HG-U133A) contained 64 samples, 38
from healthy donors and 26 from AML patients. The challenges of
surmounting the heterogeneity have led researchers to use high-
throughput technology in an attempt to identify genes with
abnormal expression for the development of specific and less toxic
therapies [14].
Cervical cancer is the second most common type of cancer in
women worldwide and the majority of advanced cases detected die
[19,20]. Cervical cancer cells show karyotype alteration complex-
ity and it is thought that characterisation of this genetic variability
will help reveal genes paramount to cervical cancer development
[13]. The dataset on cervical cancer (GSE9750, of type HG-
U133A) contained a total of 66 samples, 24 of which were normal
cervical epithelium, 33 primary tumours and 9 cell lines. In our
analysis the 9 cell lines were omitted to reduce variability.
Breast cancer is the most common cancer among women.
Estrogen hormones are important regulator of physiological
processes, and they play a role in breast cancer cell proliferation
by binding to their target receptor [21] and therefore offer a
therapeutic avenue to treatment by antagonism of estrogens actions
[22]. Letrozole, an aromatase inhibitor, was applied to breast
cancer patients in the last case study and genetic profiles were
examined. The dataset (GSE5462, of type HG-U133A) contained
116 samples in a paired study taking biopsies before and after (10–
14 days) letrozole treatment and it offered a different scenario from
the first two datasets for the connectivity mapping exercise.
Results
Acute Myeloid Leukemia
The AML gene signature. Two-sample t-tests (26 AMLs vs
38 Healthy) on the AML dataset returned 186 significant
differentially expressed genes with an expected number of false
positives (ENFP),1. This list was then filtered by removing those
genes whose mean log2 expression intensities were below 6 in both
the healthy and AML groups. The setting of a minimum log2
intensity at 6, although somewhat arbitrary, was based on our
previous experience working with Affymetrix arrays, the rationale
being that bright probes with fluorescence intensity above certain
threshold give more reliable results. This filtering by probe intensity
reduced the gene list to 118. Adding a further stringency by
analyzing the fold changes, where accepting a threshold .1 for the
absolute log2-ratio reduced the list to 105 significant genes. In order
to derive a representative gene signature, different lists were
compiled with the first 105, 50, 30, 20 and 10, of the top ranked
genes by p-value. sscMap analyzed these gene signatures of different
length and the n~30 gene signature was determined to be the one
that returned a list of candidate compounds of significant length,
and was further analyzed by the perturbation method. Creating 30
perturbation signatures based on the original n~30 gene signature,
these 31 gene signatures together werere-analyzed by sscMap and a
perturbation stability of each candidate connection was obtained.
The connections to drugs. The AML case study gave five
compounds with significant inverse connections to AML (see top
of Table 1). Inverse connection here refers to a connection with
negative setscore defined by Eq.(6) in [5]. A negative setscore
indicates that the biological state collectively represented by the
reference set is opposing the biological state represented by the
gene signature. In this particular case with AML, it means that
these candidate compounds all have potential effects of countering
the AML disease state. Each candidate was then ranked by their
setsize (SetS) if in the case where the perturbation stabilities (PS)
are equal. There was only one candidate with a perturbation
stability 1. This suggests that the compound 5186223 was a stable
candidate throughout the perturbation experiment even though it
had a setszie of 1. The SetSs for the the candidates varied from 4
to 1 which were low but the inverse connections retrieved were
relatively strong, represented by negative setscores ranging from
20.3879 to 20.2377.
The literature for 5186223 is scarce and Prestwick-691, the next
ranked candidate, follows suit with a dearth of information
available. The aromatic retinoid TTNPB has been shown to play a
key role in decreasing the proliferation of melanoma cells under
rexinoid and retinoid treatment [23]. Co-dergocrine mesilate
works by stimulating presynaptic dopamine receptors which
inhibits norepinephrine secretion, with norepinephrine having
Gene-Signature Perturbation Connectivity Mapping
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Iloprost, a synthetic prostacyclin analogue, has been suggested as a
candidate therapeutics to cancer. It decreases tumour cell
adhesion to endothelium by binding to the prostacyclin receptor
and is reported to have antimetastatic effects [25]. All these five
compounds have a negative connection score to the AML gene
signature, suggesting that they may serve as candidate drugs to
treat AML, or more precisely, they all have the potential to push
the biological state represented by AML patients back closer to the
biological state represented by healthy donors.
Adverse compounds retrieved by the AML case study gave a list
of four compounds with a perturbation stability of 1 and a SetS of
at least 5, bottom of Table 1 (solasodine, tranylcypromine, dilazep
and neomycin). Solasodine is a glycoalkaloid, which may have a
role in skin cancer protection [26]; tranylcypromine is a
monoamine oxidase inhibitor, with monamine oxidase down-
regulation a potential indicator of cancer risk [27]; dilazep is an
inhibitor of equilibrative transport of nucleotides [28]; and
neomycin is an inhibitor of phospholipase C which has an
important role in signal transduction pathways. This list, was
again, filtered to include candidates that withstood the perturba-
tion stability test (bottom of Table 1). Candidates were ranked by
their PS and then by SetS in decreasing order. SetNos ranged
from 0.1551 to 0.2588. The fact that these compounds have
positive connections to AML indicate that they can elicit a
transcriptional response similar to that observed in AML.
Generally, compounds with strong positive connections to a
disease signature are not to be used as candidate therapeutics to
that disease. However, their known mode of actions could
nevertheless provide valuable insights about the mechanisms
which are impaired or compromised in the disease state. A
comprehensive list of drugs connected to the AML gene signature
can be found in the supplementary Table S1.
Cervical cancer
In the cervical cancer case study a list of 575 genes were
obtained with an ENFP ,0.1. Filtering the genes by requiring a
minimum of log2 intensities of 6 in both groups, and an absolute
log2 expression ratio of above 1, a list of 210 significant genes with
p-value v1:05|10{7 were obtained. Gene signatures were then
formulated containing 210, 100, 50, 30, 20 and 10, top ranked
genes, as above. These gene signatures of different lengths were
then put to sscMap and the number of significant compounds
examined, the gene signature of n~100 was deemed the most
worthy for further scrutinising by the perturbation method, as
there were only two candidate drugs for the 50-gene signature and
returning no candidates for any of the shorter profiles. Perturba-
tion signatures were generated, and together with the original one,
these were put to sscMap and results analysed. The list of drugs
with significant connections to the cervical cancer gene-signature
were then sorted by their perturbation stability. Figure 1 shows the
significant connections in relation to setscore against setsize (green)
with effectors with high perturbation score and setsize highlighted
other than green.
The connections to drugs. The cervical cancer case study
returned a list of 16 candidate compounds with a PS of 1 whose
expression profiles were inversely connected to the cervical cancer
gene signature (see top of Table 2). The top candidates with high
setsize were trichostatin A, fluphenazine and 15-delta
prostaglandin J2. Trichostatin A, a histone deacetylase (HDAC)
inhibitor, has been used in cancer research; it offers a novel
approach to treating chemoresistant tumours by enhancing
sensitivity to DNA damaging agents [29]. Fluphenazine is an
anti-psychotic drug and a member of the phenothiazine group,
which have been proposed as having an antiproliferative effect and
may be successful as anticancer agents [30]. 15-delta prostaglandin
J2 has been shown to demonstrate inhibition of cell proliferation in
cancers by peroxisome proliferator-activated receptor-gamma-
dependent and -independent mechanisms [31].
There were 3 drugs that had positive connection scores to the
cervical cancer signature with a perturbation stability of 1 and a
SetS of 5 (diphemanil metilsulfate, riluzole and sulfamethoxazole)
along with genistein and paclitaxel which had w95% PS but a
larger SetS. Diphemanil metilsulfate, riluzole and sulfamethoxa-
zole had setscores ranging from 0.1180 to 0.0853 (top of Figure 1).
Diphemanil metilsulfate is a synthetic quaternary ammonium
compound [32], but little is known of its use in cancer research.
Riluzole, an ion channel modulator, has been shown to
demonstrate by estrogen receptor stress an inhibition of DNA
synthesis and apoptosis in certain cell lines [33]. Sulfamethoxazole,
an antibacterial agent, has been used for treatment of infections in
patients with cancer, in combination with trimethoprim with
minimal toxicity [34]. A comprehensive list of drugs connected to
the Cervical cancer gene signature can be found in the
supplementary Table S2.
Letrozole treated breast cancer
The letrozole treated breast cancer study was an example where
the opposite direction to previous examples was sought. Here we
would be looking for compounds that have a similar effect as
letrozole, with candidates in the adverse list having a role that was
contrasting with letrozole. In compiling the gene signature, t-tests
returned a list of 33 genes using a ENFP ,3. Since this was a
manageable list, and probably related to the direct effect of the
treatment, no further stringency filters were applied thus removing
experimenter involvement. As in the above two cases, signatures
were created using 33, first 20 and first 10 of the most significant
genes. They were analysed by sscMap and based on the number of
drugs the gene signature of n~10 was selected for the
perturbation analysis as described in the examples above. The
n~10 signature returned a list of 461 drugs with significant
Table 1. Compounds with significant connections to the AML
gene signature.
REF TabNo SS PS SetNo SetS
5186223 31 31 1 20.3879 1
Prestwick-691 31 28 0.9032 20.3437 3
TTNPB 31 17 0.5484 20.3049 2
co-dergocrine
mesilate
31 15 0.4838 20.2377 4
iloprost 31 12 0.3871 20.2796 3
neomycin 31 31 1 0.1705 5
dilazep 31 31 1 0.1922 5
tranylcypromine 31 31 1 0.2588 5
solasodine 31 31 1 0.1551 6
Those at the top of the table with negative setscores are candidates that may
inhibit the AML phenotype. At the bottom of the table with positive setscores
are compounds that may elicit a transcriptional response similar to that of AML.
REF is the (drug) name for the reference set; TabNo (~nz1) is the total number
of gene signatures used in the perturbation analysis; SS is the total number of
significant connections to REF from those (nz1) signatures; PS is the
perturbation stability ~SS=TabNo, and SetNo is the setscore; SetS is the
setsize.
doi:10.1371/journal.pone.0016382.t001
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perturbation stability 1. The return of 304 compounds is a
reflection of the signature compiled as a result of the t-test, that
would appear to have diverse effects on specific genes. As this was
a large number, the list was furthered filtered by setsize. In total 30
candidate drugs with positive connection scores were retrieved
satisfying PS=1 and SetS n~w6 (see top of Table 3). The SetS
for this list ranged from 19 to 6 with SetNos from 0.6797 to
0.2719.
The connections to drugs. The top-ranking compounds,
shown in Figure 2, had two representative phenothiazines;
chlorpromazine and fluphenazine. Chlorpromazine has shown
cytoxicity towards cancerous cell lines, and there is evidence to
suggest that there may be antineoplastic effects of antipsychotic
drugs in general, with schizophrenia patients receiving
antipsychotic medications having reduced cancer risk [35]. 15-
delta prostaglandin J2 was also present along with
nordihydroguaiaretic acid and resveratrol. Nordihydroguaiaretic
acid, a 5-lipoxygenase inhibitor, has been shown to act as a lead
compound with the ability to induce a type of apoptosis (anoikis),
with no detectable toxicity [36]. Resveratrol, a naturally occurring
phytoalexin present in grapes, has been studied for its therapeutic
effects in cancer and its chemotherapeutic and chemopreventive
abilities [37].
For opposite connections, the letrozole treated breast cancer
datasets generated a list of 6 compounds where SetS was w6 with
perturbation stability of 1, (lower half of Figure 2), with estradiol
included for a w90% PS, being present in 10 of 11 stability tests,
because of its large SetS of 37. The SetS ranged from 6 to 37 with
the SetNos ranging from 20.5622 to 20.1921. The top-rated
compounds were wortmanin and genistein. Wortmannin, an
inhibitor of PI3K, and genistein, a phytoestrogen down-regulating
tyrosine kinase, have been used in cancer research demonstrating
inhibition of cancer motility and EGFR signaling inhibition,
respectively [38,39]. A comprehensive list of drugs connected to
the Letrozole-treated breast cancer gene signature can be found in
the supplementary Table S3.
Discussion
Acute Myeloid Leukemia
AML is a heterogenous disease, where targeted therapies have
arisen to look at histone deacetylase inhibitors, demethylating
agents, farnesyltransferase and FLT-3 inhibitors, but where the
first targeted therapy is all-trans-retinoic acid (ATRA) [40]. The
results presented in Table 1 supplied two candidates for which
information is quite minimal in terms of cancer treatment,
5186223 and Prestwick-691, so interpretation of their usefulness
as therapeutics is restrained and poses interesting laboratory
experiments and a reminder of the information that may not be
currently available in drug discovery.
TTNPB is a retnoic acid that binds to the retinoic acid receptor
(RAR), which is an appealing connection given the amount
literature on ATRA for treatment of an AML subtype acute
promyelocytic leukemia [41,42]. It has been reported that AML2
and AML1 expression can be induced by retinoic acid with ATRA
having reduced effect on non-M3 AML (any type other than acute
promyelocytic leukemia) as it acts on the RAR pathway[43,44].
Despite this retinoid differentiation therapy has shown promising
results in vitro [45]. Recently, Tsai et al. have suggested that a high
affinity retinoic X receptor (RXR) may be a candidate for non-M3
AML treatment, stating also that this is possible through co-
stimulation of both RAR and RXR receptors to be involved in the
differentiation of non-M3 AML [46]. It was interesting that
iloprost was present. Iloprost has been shown to inhibit tumour
formation by the role of activation of PPARc nuclear receptors
Figure 1. setscore-vs-setsize plot of significant connections to the cervical cancer signature. Green- significant connections; Blue-
significant negative connection setscores with high PS and large setszie; Red- significant positive connection setscores with high PS and large setsize.
doi:10.1371/journal.pone.0016382.g001
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Factor-b (TGF-b), a cytokine which promotes differentiation of
Th17 cells. Th17 cells have been said to progress or aid in
development of AML [48]. This connection was a demonstration
of the multiple pathways and diversity of targeted therapeutics and
an advocate for laboratory research in understanding the most
beneficial treatments for individuals. Co-dergocrine mesilate as a
candidate therapeutic was an interesting finding as being an
inhibitor of norepinephrine it may play a role in the decrease of
cancer proliferation by stimulating presynaptic dopamine recep-
tors. It has also a role in its activation having an effect on gene
expression in estrogen-stimulated TGF-a [49].
Cervical cancer
The cervical cancer results showed by way of the top ranked
candidates in the adverse list that estrogen is a factor in candidate
selection, and it has been shown that estrogen receptor alpha
(ERa) is an important instigator in cancer [50]. This would explain
the presence of the estrogen related pathways in the adverse list
(top half of Figure 1), with riluzole and genisten cited. Diphemanil
metilsulfate has no apparent information on its effects in cancer
and Sulfamethoxazole being used as an antibacterial therapeutic.
The sscMap’s ability to select these candidates demonstrates its
heightened sensitivity to the significant list of genes analysed. The
fact that the top ranked adverse candidates are either estrogen
related or impervious to cervical cancer is evidence that they may
be ineffective in altering the phenotype of the disease favourably.
The top therapeutic candidates in Figure 1 (lower half) being
trichostatin A, fluphenazine and 15-delta prostaglandin J2 were
regarded as good hits with trichostatin A (TSA) already being used
in studies to treat cervical cancer in combination with bortezomib
and seen to retard tumour growth [51]. Fluphenazine as a
member of the phenothiazine family has been used as an
antipsychotic drug but studies have shown that they have an
ability to induce apoptosis and demonstrate anti-tumour activity in
vivo [30]. 15-delta prostaglandin J2 has been demonstrated to
induce growth arrest or inhibition in several tumors and cancer
cell lines including breast and colon through an activation of
PPARc [31,52]. That these three top hits have differentiating
applications demonstrates the genetic variability in cervical
cancers. Recent treatments have tended towards epidermal growth
factor receptor (EGFR) and vascular endothelial growth factor
VEGF signalling pathways with therapeutics focusing on adeno-
sine triphosphate inhibitors and monoclonal antibodies [53]. All
three candidates have been shown in studies to have an effect on
the EGFR pathway with TSA having been shown to enhance
sensitivity of TRAIL-resistant ovarian cancer cells by inhibition of
the EGFR pathway [54]. Fluphenazine is a calmodulin inhibitor,
with calmodulin mediating the elevations of intracellular Ca2+
activating EGFR-dependent signalling [55]. This is an indication
that the gene signature analysed by the sscMap retrieved selective
therapeutics by virtue of connections between strong candidates.
The n~100 signature was a quite long list of pertinent genes,
which could have led to variable results. This is an important
aspect of the perturbation approach, which can remove ‘weaker’
candidates by placing them further down the list which acts as an
indicator of their resolve. The candidates represented in the
bottom half of Table 3 suggests a similar transcription response to
the disease. They had strong attributes in PS and SetSize,
therefore suggesting of their inability to benefit the disease
phenotype. As stated above, the fact that ERa is an important
instigator supports the candidates in the bottom half of Table 3
(estrogen related or impervious to cervical cancer).
Letrozole treated Breast cancer
As letrozole, an aromatase inhibitor, offers a reduction of estrogen
production it would seem likely that the drugs that would be present
in the adverse list (Figure 2 lower half), would be compounds related
to estrogen and estrogen receptor targets. This is the case with the
selection ofwortmannin, aninhibitor of PI3k, beingshownto have no
effect on estrogen deprived cell lines [22]. Wortmannin in that
particular study was used to inhibit the PI3K/AKT pathway to
restore cell sensitivity to tamoxifen (an antiestrogen) to show the
interaction between the ER and growth factor receptor pathways.
Also present were estradiol, genistein (phytoestrogen) and diethylstil-
bestrol (asynthetic estrogen) which were indicators of possibleadverse
effectsasallthesecompoundswouldcontrasttheeffectbeingafforded
by letrozole therapy. Diethylstilbestrol was a drug administered to
women during pregnancy to prevent miscarriage (from 1940s to
1960s) that now show higher increased rates of breast cancer. Their
daughters, now at an age for diagnosis, also have an increased
incidence of breast cancer, with a rate ratio of 2.5 compared to non-
diethylstilbestrol-exposed [56–58].
The top therapeutic candidates that were supplied in Figure 2
(top half), (chlorpromazine, fluphenazine, 15-delta prostaglandin
J2, nordihydroguaiaretic acid and resveratrol) are all strong
Table 2. Compounds with significant connections to the
cervical cancer gene signature.
REF TabNo SS PS SetNo SetS
trichostatin A 101 101 1 20.1124 182
fluphenazine 101 101 1 20.0953 18
15-delta
prostaglandin J2
101 101 1 20.1109 15
gossypol 101 101 1 20.1532 6
pyrvinium 101 101 1 20.1452 6
rofecoxib 101 101 1 20.087 6
clotrimazole 101 101 1 20.1205 5
5155877 101 101 1 20.1218 4
5707885 101 101 1 20.143 4
etoposide 101 101 1 20.1358 4
puromycin 101 101 1 20.1767 4
semustine 101 101 1 20.182 4
thiostrepton 101 101 1 20.1414 4
etacrynic acid 101 101 1 20.1464 3
rottlerin 101 101 1 20.1582 3
MS-275 101 101 1 20.2238 2
genistein 101 97 0.9604 0.076 17
paclitaxel 101 100 0.9901 0.0881 6
sulfamethoxazole 101 101 1 0.0853 5
riluzole 101 101 1 0.1007 5
diphemanil
metilsulfate
101 101 1 0.1180 5
Those at the top of the table with negative setscores are candidates that may
inhibit the cervical cancer phenotype. At the bottom of the table with positive
setscores are compounds that may elicit a transcriptional response similar to
that of cervical cancer. REF is the (drug) name for the reference set; TabNo
(~nz1) is the total number of gene signatures used in the perturbation
analysis; SS is the total number of significant connections to REF from those
(nz1) signatures; PS is the perturbation stability ~SS=TabNo, and SetNo is
the setscore; SetS is the setsize.
doi:10.1371/journal.pone.0016382.t002
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zine and fluphenazine) are drugs used to treat bipolar and
psychotic disorders, with chlorpromazine having been demon-
strated to have moderate inhibitory effects on BCRP (the breast
cancer resistance protein), thus reducing its multidrug resistance
effects [59]. Resveratrol has many applications in cancer research,
as it inhibits cellular events linked with initiation, promotion and
progression [60]. 15-delta prostaglandin J2 are emerging as potent
antitumour agents, being shown to have growth inhibitory effects
and apoptotic capabilities [61]. Nordihydroguaiaretic acid,
Resveratrol and 15-delta prostaglandin J2 are therapeutics
involved in prostaglandin inhibition [61–63], in turn prostaglandin
is a potent inducer of aromatase expression, also induces
Ciclooxygenase-2 (COX-2) expression [64], and has a role in
carcinogenesis. This pathway is also exploited by letrozole which
has been shown to block the aromatase up-regulated by
prostaglandin [65], and there would be an obvious connection
between these therapeutics.
Table 3. Compounds with significant connections to the gene signature for letrozole treatment in breast cancer.
REF TabNo SS PS SetNo SetS
chlorpromazine 11 11 1 0.4022 19
fluphenazine 11 11 1 0.2719 18
15-delta prostaglandin J2 11 11 1 0.4478 15
nordihydroguaiaretic acid 11 11 1 0.3359 15
resveratrol 11 11 1 0.6157 9
0179445-0000 11 11 1 0.4072 8
carbamazepine 11 11 1 0.3911 8
deferoxamine 11 11 1 0.5074 8
indometacin 11 11 1 0.3732 8
methotrexate 11 11 1 0.5323 8
felodipine 11 11 1 0.4632 7
nifedipine 11 11 1 0.3734 7
0173570-0000 11 11 1 0.6153 6
0175029-0000 11 11 1 0.6159 6
beta-escin 11 11 1 0.455 6
citiolone 11 11 1 0.4647 6
cloperastine 11 11 1 0.5028 6
cotinine 11 11 1 0.6079 6
dipyridamole 11 11 1 0.6797 6
ethotoin 11 11 1 0.5104 6
eucatropine 11 11 1 0.5135 6
gossypol 11 11 1 0.3725 6
ketoprofen 11 11 1 0.3953 6
lomefloxacin 11 11 1 0.3204 6
loperamide 11 11 1 0.3829 6
meclofenoxate 11 11 1 0.3914 6
medrysone 11 11 1 0.6724 6
oxaprozin 11 11 1 0.4627 6
Prestwick-674 11 11 1 0.4868 6
tinidazole 11 11 1 0.3298 6
estradiol 11 10 0.9091 20.1921 37
diethylstilbestrol 11 11 1 20.5198 6
alprostadil 11 11 1 20.4043 7
PHA-00745360 11 11 1 20.5073 8
fludrocortisone 11 11 1 20.5622 8
genistein 11 11 1 20.3865 17
wortmannin 11 11 1 20.3153 18
Those at the top of the table with positive setscores can elicit a transcriptional response similar to that of letrozole. At the bottom of the table with negative setscores
are compounds that may elicit a transcriptional response opposite to that of letrozole. REF is the (drug) name for the reference set; TabNo (~nz1) is the total number
of gene signatures used in the perturbation analysis; SS is the total number of significant connections to REF from those (nz1) signatures; PS is the perturbation
stability ~SS=TabNo, and SetNo is the setscore; SetS is the setsize.
doi:10.1371/journal.pone.0016382.t003
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have a strong involvement in cancer treatment or may act in a
similar pathway as letrozole suggesting that the gene signature,
although containing only n~10 genes (probesets), could accurately
summate the pertinent expression levels in the dataset. The list of
compounds in Figure 2 demonstrate the utility of the enhanced
significance selection process offered by the gene-signature
perturbation method.
The strength of the perturbation approach
The strength of the perturbation approach in its ability to rank
therapeutics can be gauged by contrasting Table 2 and Table 4 of
the cervical cancer case study, with Table 4 ranking candidates
without implementing the perturbation stability measure. Without
the ability to achieve a manageable list length it creates an issue of
where to decide to stop looking for candidates, with Table 4 being
thresholded at SetS greater than 4. Of course we would expect the
top couple of candidates to be present in both tables as having a
large SetS and SetNo would be indicator that the original sscMap
was able to retrieve strong candidates. Here we can see trichostatin
A, fluphenazine and 15-delta prostaglandin J2 have performed
well in both Tables. Perturbation has the ability to filter the
candidates already represented by their robustness and create an
advanced system of therapeutic selection. The top halves of
Table 4 and Table 2 representing the contrasting transcription
profiles, after the top 3, differ by their ability to withstand
systematic checks. This increases the confidence in the list attained
and confers more reliability in the experimenters ability to retrieve
viable candidates. The original ranking attributes, although
successful, fail to convey any increased ability of one candidate
over another. The perturbation enhancement delivers in the
ability to derive if this is a strong candidate, and can be utilised in
tandem with these other attributes, as is the case with genistein,
where in Table 4 it is the top candidate in the similar transcription
profile to the disease phenotype(and we would have expected it to
be there) but this is not the case when we check for robustness
where it moves further down the ranking. Thus it implies that
checking for robustness can be a deciding factor in the ability to
decide therapeutic selections, reduce list sizes and increase the
potential of altering the phenotype.
Conclusions
Differential gene expression offers a viable window into the
complexity of the cellular response to deviation from normal
activity and to drug treatment. Gene-expression connectivity
mapping is an important technological development for the
establishment and interpretation of connections among genes,
drugs, and diseases. The gene-signature perturbation approach is a
further advance towards robust and effective connectivity
mapping. It was conceived in an attempt to gauge the stability
of an identified compound’s connection to gene signatures. This
extended approach is favourable over the existing technique,
which lists the results by either the setscore or setsize, in assessing
the therapeutics influence on the compiled signature. This offers
insight into pertinent genes as well as therapeutic selection. It
removes experimenter influence in assessing therapeutic applica-
tive assumptions by unveiling their accountability to perturbation.
The merits of using the sscMap software have been previously
addressed [5,6], this now coupled with an unbiased method of
therapeutic selection enhances its utility.
The case studies we have analysed here returned favorable
results and insightful leads. For the letrozole treated breast cancer
case, we could see an obvious ‘trend’ occurring in the results with
adverse compounds being those of an estrogen derived pathway, in
contrast to the favourable candidates with hypothesised similarity
in effect. These were comparable by the mode of action with the
Figure 2. Significant connections to the letrozole treatment signature in breast cancer. Green- significant connections; Blue- significant
positive connection setscores with high PS and large setsize; Red- significant negative connection setscores with high PS and large setsize.
doi:10.1371/journal.pone.0016382.g002
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theme in the top hits retrieved. The results of the AML case study
supplied interesting candidates with, among others, a potent
retinoic acid TTNPB. The fact that ATRAs are used as
therapeutics for AML suggests this is a very interesting connection
list with very little known about the two candidates ranked above
(5186223 and Prestwick-691), which offers an intrigue to their
potential use. The cervical cancer results for the top ranked
candidate compounds revealed a strong association with the
EGFR pathway. These results demonstrate the ability of the
perturbation method to make incisive interpretations achieved
with varying sizes of gene signatures ranging from 10 in the
Letrozole study, to 100 in the cervical cancer study.
The perturbation approach is a conceptually simple but
practically useful idea; it added real value to the connectivity
mapping process allowing for increased specificity in the
identification of possible therapeutic candidates. The ‘strength’
of each candidate compound derived from checking for robustness
against perturbation offers a viable unbiased method of candidate
selection for further experimentation. Embracing such criteria is
an important aspect of enhancing research in drug discovery
establishing potential uses for existing drugs in diseases that have
poor prognosis. Future direction will likely lend itself to the
understanding of ideal gene signature size to reduce user selectivity
and offer a more pragmatic approach. It is very much needed now
in connectivity mapping to develop a systematic and coherent
procedure or protocol that enables biomedical researchers to
construct high quality gene signatures and determine their optimal
lengths automatically. One possible strategy to achieve this, when
the number of differentially expressed genes is large from
microarrays, is to try to incorporate other biological knowledge
in constructing gene signatures, for example, by requiring the
genes included in a signature belonging to a small number of
dominate pathways or biological processes. This will entail
sophisticated computational procedures involving the retrieving
and compiling of existing biological knowledge from external
databases such as GO, KEGG PATHWAY, and NCI-Nature
PID. We see future research in this direction to be greatly
beneficial to gene-expression connectivity mapping and its wide
applications.
Methods
The Perturbation approach
In this section we describe the procedures of the perturbation
approach to connectivity mapping. A gene-signature, as described
in previous studies [3,5], is a concise list (threshold applied by a
mathematical variable) of statistically differentiated genes with
their regulation status (up or down) specified, which collectively
characterise the biological state of a researcher’s interest. A gene-
signature is usually the result of some gene-expression profiling
(e.g. DNA microarray) experiments investigating a particular
biological condition, with the most significantly differentially
expressed genes selected. A gene-signature should capture the
most prominent feature(s) of the biological state it represents, while
a reference gene-expression profile, in the context of connectivity
mapping, represented in non-parametric fashion, is intended to
provide a more comprehensive description of the reference state.
This reference gene-expression profile contains rank-ordered
genes of a profile compared to a vehicle treated control. There
are currently 6100 individual reference gene-expression profiles in
the sscMap core-database, each representing a biological state
induced by treating cells with a compound as compared to vehicle
control. In total 1309 compounds were represented with 4{5
microarray hybridisations per compound on average (the actual
number of hybridisations with each compound varies). In this
study, all individual reference profiles with the same compound
are designated as belonging to a reference set, and SetSize refers to
the number of microarray hybridisations with that compound.
Hence a set of reference profiles with the same compound
(a reference set) collectively characterise the effects of that
compound.
Connecting a gene signature to reference sets. For a
given gene-signature, whether it is the original signature, or a
perturbation signature (see below for detailed definition) derived
from the original one, we calculate a connection score (setscore)
between the signature and each set of reference profiles, and also
calculate the associated p-value using the method described in [5].
If the p-value is lower than a pre-set threshold, the connection is
declared as statistically significant. In our connectivity mapping
exercise we always set the threshold p-value as 1=Nset, where Nset
is the total number of reference sets being queried. By setting the
threshold p-value as such, we expect to have one false connection
per gene-signature. A false connection means that whereas in
reality there is no connection between the gene-signature and the
reference set, the p-value happens to be lower than the threshold
purely by chance.
Generating perturbation signatures. Suppose s is a gene-
signature of length n, where n is the number of genes (probesets) in
the signature. We can generated n perturbation gene-signatures of
length (n{1) by taking one gene out each time, with replacement.
We shall use s’
i to denote a perturbation signature in which the ith
Table 4. Without using the perturbation analysis this table
(thresholded at SetS$5) lists compounds with significant
connections to the cervical cancer gene signature.
REF SetS GeneLen SetNo
trichostatin A 182 100 20.1124
fluphenazine 18 100 20.0953
15-delta prostaglandin J2 15 100 20.1109
resveratrol 9 100 20.0904
0179445-0000 8 100 20.0927
gossypol 6 100 20.1532
pyrvinium 6 100 20.1452
rofecoxib 6 100 20.0870
clotrimazole 5 100 20.1205
halcinonide 5 100 20.1188
trimethoprim 5 100 0.0812
sulfamethoxazole 5 100 0.0853
riluzole 5 100 0.1007
naphazoline 5 100 0.0888
iproniazid 5 100 0.1117
hydrochlorothiazide 5 100 0.0898
guanadrel 5 100 0.1103
diphemanil metilsulfate 5 100 0.1180
prilocaine 6 100 0.0582
paclitaxel 6 100 0.0881
genistein 17 100 0.0760
REF is the (drug) name for the reference set; SetS is the setsize; GeneLen is the
length of gene signature; SetNo is the setscore.
doi:10.1371/journal.pone.0016382.t004
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that this is a perturbation signature.
Perturbation stability. For each of the nz1 gene-signatures
(one original plus n perturbation signatures), we use sscMap to
establish the connections between the signature and the Nset
reference sets, and use the criteria described above to determine
whether the connections are statistically significant or not. For
each reference set T, its connections to the original gene signature
s and the n perturbation gene-signatures s’
is are examined. If the
connection between signature s and the reference set T is
statistically significant, then we examine whether T also has
significant connections to the n perturbation signatures. We define
‘‘perturbation stability’’ as the proportion of significant
connections out of the total number nz1. So a perturbation
stability 1 means that not only the reference set has a significant
connection to the original signature s, but also the reference set has
significant connections to all the perturbation signatures s’
is
derived from the original one. Our rationale of introducing the
perturbation stability is to test whether a discovered connection is
robust and stable enough against small changes in the signature
(perturbations). An analogy to this exercise in the physical world is
that to test whether a physical object stands stable, you can give it
some small pushes from all different directions to see if it still
stands. The perturbation stability gives us an effective measure to
analyse the sometimes large number of significant connections in
the connectivity mapping exercise. It allows us to concentrate on
those connections that are most stable and thus increases the rate
of success in following-up investigations.
Data collection, processing, and analysis. The zipped
files for each of the three case studies were downloaded from GEO
website was extracted to reveal the array data file. The R package
software of Affymetrix Micro Array Suite 5.0, MAS5, was used to
extract the expression data for each of the arrays in the three
studies. Each of the individual studies arrays were separated into
control and effector groups with their relevant expression
incorporated into a single file for statistical analysis. As with the
Lamb et al. analysis, normalisation was not incorporated. The gene
signature was formulated by compiling the samples gene-
expression levels, separated into control/treatment and the
formulation of statistical difference by t-test. Ranking these genes
by the t-test results supplied a list of significant genes determined
by the expected number of false positives. All gene signatures were
then analysed by sscMap, which has a built-in core database for
over 6000 gene expression profiles. A prerequisite is the use of (or
conversion to) Affymetrix HG-U133A probe-set IDs.
The sscMap reads gene signature files in tab delimited format
with a column containing the Affymetrix IDs and also a column
for indication of increased or decreased expression (+1o r21).
Once executed an output file is generated that includes candidate
compounds with significant connections to the signature. Given a
particular gene-signature of interest, a list of all possible
perturbation signatures are derived. The connectivity mapping is
then carried out on all the perturbation signatures and the original
one, and a data matrix of the connections’ significance index can
be compiled, by the summation of the therapeutic instances per
list, thus incorporating all the results. Each connection’s ‘strength’
is based on its ability to remain unperturbed by the absence of a
single gene, which is quantified by the perturbation stability
described in the previous section.
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